Targeting Replication Stress in Cancers with Adavosertib, the First in Class WEE1 Inhibitor

Time: 12:30 pm
day: Day One


  • Delving into WEE1 inhibitors, which have the potential for monotherapy activity in cancers with high levels of basal replication stress
  • In this monotherapy scenario, in addition to the G2/M checkpoint override resulting from CDK1 deregulation, the activation of CDK2 appears to be the main driver with downregulation of RRM2 and dNTP reduction observed
  • Exploring combination of adavosertib with the PARP inhibitor olaparib can overcome of PARPi resistance in both preclinical models and based on emerging data, in the clinic